An independent two-stage DCF analysis by a frontier AI model.
Dexcom has fundamentally altered diabetes management, shifting the paradigm from painful, episodic fingersticks to continuous glucose monitoring (CGM). With its FDA-approved technology—dating back to its early Seven Plus models and evolving to its modern sensors—the company has created an exceptionally sticky ecosystem. Once a patient is prescribed a Dexcom sensor and integrated into its software analytics, the likelihood of switching to a competitor drops significantly, creating highly predictable, recurring revenue.
The core of Dexcom's long-term valuation lies in expanding its Total Addressable Market (TAM). While it commands strong penetration in the Type 1 diabetes demographic, the massive opportunity lies in Type 2 diabetes and preventative health. Currently generating over $1.07 billion in Free Cash Flow (driven by $1.44B in Operating Cash Flow offsetting its heavy CapEx needs), Dexcom possesses the financial firepower to continuously fund R&D and scale global manufacturing, sustaining its competitive edge against rivals like Abbott.
A 15.0% growth rate acknowledges Dexcom's immense runway in penetrating the broader Type 2 diabetes population globally. As manufacturing scales in Malaysia and Ireland, margins should further expand, driving robust free cash flow compounding.
An 8.5% discount rate balances Dexcom's wide regulatory moat and sticky recurring revenue model against the inherent risks of single-product dependency, competitive pricing pressures, and complex reimbursement landscapes.
A 3.0% terminal growth rate reflects standard long-term healthcare inflation and GDP expansion. While CGM technology will remain vital, long-term hyper-growth is mathematically constrained by market saturation over decades.
Intrinsic value per share under varying discount rate and terminal growth rate assumptions.
| WACC ↓ / Terminal → | 2.0% | 2.5% | 3.0% | 3.5% | 4.0% |
|---|---|---|---|---|---|
| 2.0% | $95.82 | $78.40 | $66.34 | $57.49 | $50.73 |
| 2.5% | $107.80 | $86.24 | $71.87 | $61.60 | $53.90 |
| 3.0% | $123.20 | $95.82 | $78.40 | $66.34 | $57.49 |
| 3.5% | $143.73 | $107.80 | $86.24 | $71.87 | $61.60 |
| 4.0% | $172.48 | $123.20 | $95.82 | $78.40 | $66.34 |
■ Undervalued vs current price ■ Overvalued vs current price
A 15% growth rate reflects the ongoing, rapid global adoption of continuous glucose monitoring technology. Dexcom has significant runway remaining as insurance coverage expands for the massive Type 2 diabetes population, fueling double-digit top-line growth that will cascade to cash flow.
An 8.5% discount rate was selected. This relatively standard rate balances the company's strong economic moat and recurring revenues against its concentration risk (relying heavily on a single product category) and intense competition from massive healthcare conglomerates.
Free Cash Flow was estimated by taking Net Cash Provided by Operating Activities (approximately $1.44B) and subtracting cash used for capital expenditures (approximately $363M), arriving at an estimated FCF base of roughly $1.07B.
Disclaimer: The numbers presented on this page are for educational and entertainment purposes only. They are the result of a deterministic mathematical model fed with assumptions generated by an Artificial Intelligence (Gemini 3.1). This does not constitute investment advice. Always conduct your own due diligence before investing in the stock market.